As vasodilation, particularly in skeletal muscle, is crucial to glucose disposal (Keske et al., 2017), carvedilol's ability to maintain or improve vascular function may lead to better glycemic control in patients with diabetes than other inhibitors selective for β1‐AR (Haas et al., 2003; Jacob & Henriksen, 2004). Here, ADRB1 is linked to diabetes mellitus.